9.63
0.73%
0.07
Pre-market:
9.72
0.09
+0.93%
Regenxbio Inc stock is traded at $9.63, with a volume of 800.04K.
It is up +0.73% in the last 24 hours and down -13.24% over the past month.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
See More
Previous Close:
$9.56
Open:
$9.56
24h Volume:
800.04K
Relative Volume:
1.33
Market Cap:
$474.71M
Revenue:
$89.04M
Net Income/Loss:
$-241.08M
P/E Ratio:
-1.5237
EPS:
-6.32
Net Cash Flow:
$-194.72M
1W Performance:
-9.75%
1M Performance:
-13.24%
6M Performance:
-39.32%
1Y Performance:
-51.92%
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
RGNX | 9.63 | 474.71M | 89.04M | -241.08M | -194.72M | -6.32 |
VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-01-23 | Initiated | Stifel | Buy |
Jun-02-23 | Initiated | Robert W. Baird | Outperform |
Jun-23-22 | Initiated | Berenberg | Buy |
Dec-15-21 | Initiated | Wedbush | Neutral |
Oct-19-21 | Resumed | Morgan Stanley | Overweight |
Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
Dec-16-20 | Initiated | UBS | Buy |
Jun-25-20 | Resumed | BofA/Merrill | Buy |
May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
Jun-14-19 | Resumed | Raymond James | Outperform |
Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
May-09-18 | Reiterated | Barclays | Overweight |
Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
Feb-13-18 | Initiated | Mizuho | Neutral |
Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
Chardan Capital Reiterates Buy Rating for REGENXBIO (NASDAQ:RGNX) - MarketBeat
Regenxbio surges 10% as it launches pivotal phase of muscular dystrophy asset trial - MSN
Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy - Pharmaceutical Technology
US Bancorp DE Has $26,000 Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Morgan Stanley Reiterates “Overweight” Rating for REGENXBIO (NASDAQ:RGNX) - Defense World
Raymond James maintains $18 target on RGNX after trial data - Investing.com
Regenxbio Sets Sights On 2026 Filing For DMD Gene Therapy - Citeline News & Insights
FDA endorses speedy approval path for Regenxbio Duchenne gene therapy - BioPharma Dive
REGENXBIO (NASDAQ:RGNX) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
What's Going On With REGENXBIO Shares Monday? - Benzinga
Regenxbio Share Surge 20% on Duchenne Muscular Dystrophy Treatment Trial Data, Expansion - MarketWatch
Regenxbio (RGNX) Initiates Pivotal Phase Of Affinity Duchenne® Trial Of Rgx-202 Gene Therapy And Reports Positive Functional Data - StreetInsider.com
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA - PR Newswire
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
REGENXBIO (NASDAQ:RGNX) Shares Gap Up – Should You Buy? - Defense World
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Morgan Stanley bullish on Regenxbio stock, highlights gene therapy prospects By Investing.com - Investing.com South Africa
Regenxbio down 13% ahead of data readout for muscular dystrophy asset - Seeking Alpha
REGENXBIO (NASDAQ:RGNX) Shares Gap UpWhat's Next? - MarketBeat
Redmile Group, LLC Increases Stake in Regenxbio Inc - GuruFocus.com
5 Analysts Have This To Say About Regenxbio - Benzinga
REGENXBIO's (RGNX) Overweight Rating Reaffirmed at Morgan Stanley - MarketBeat
REGENXBIO to Present First Functional Data for Novel Duchenne Gene Therapy RGX-202 | RGNX Stock News - StockTitan
REGENXBIO's SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com India
REGENXBIO FY2024 EPS Estimate Reduced by Leerink Partnrs - Defense World
REGENXBIO (NASDAQ:RGNX) Price Target Raised to $40.00 at HC Wainwright - Defense World
HC Wainwright Has Positive View of REGENXBIO FY2024 Earnings - MarketBeat
HC Wainwright Increases Earnings Estimates for REGENXBIO - Defense World
Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates - MSN
Analysts Have Made A Financial Statement On REGENXBIO Inc.'s (NASDAQ:RGNX) Third-Quarter Report - Yahoo Finance
REGENXBIO Inc. (NASDAQ:RGNX) Q3 2024 Earnings Call Transcript - Insider Monkey
REGENXBIO Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Regenxbio Inc (RGNX) Q3 2024 Earnings Call Highlights: Advancements in Gene Therapy and ... - Yahoo Finance
Regenxbio: Q3 Earnings Snapshot - The Washington Post
RegenXBio Reports Progress Amid Revenue Decline - TipRanks
Regenxbio Inc earnings missed by $0.05, revenue topped estimates - Investing.com Australia
REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates - StockTitan
Regenxbio Inc (RGNX) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
Vanguard Group Inc's Strategic Reduction in Regenxbio Inc Holdin - GuruFocus.com
Sorrento Therapeutics (OTCMKTS:SRNEQ) & REGENXBIO (NASDAQ:RGNX) Financial Survey - Defense World
REGENXBIO to Participate in Upcoming Investor Conferences - StockTitan
When (RGNX) Moves Investors should Listen - Stock Traders Daily
REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track (NASDAQ:RGNX) - Seeking Alpha
REGENXBIO (RGNX) to Release Quarterly Earnings on Wednesday - MarketBeat
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights - cnhinews.com
Assenagon Asset Management S.A. Lowers Position in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
RGNX stock touches 52-week low at $9.1 amid market challenges By Investing.com - Investing.com South Africa
RGNX stock touches 52-week low at $9.1 amid market challenges - Investing.com
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):